Advertisement

Journal of Neuro-Oncology

, Volume 94, Issue 1, pp 141–144 | Cite as

Glioblastoma in multiple sclerosis: a case report

  • Giovanni Frisullo
  • Agata Katia Patanella
  • Viviana Nociti
  • Alessandro Cianfoni
  • Raffaele Iorio
  • Assunta Bianco
  • Alessandro Marti
  • Pietro Attilio Tonali
  • Anna Paola Batocchi
Case Report

Abstract

Cerebral tumor and multiple sclerosis (MS) relapses can show overlapping clinical and magnetic resonance imaging features. In a previous study we observed in relapsing MS patients increased T-bet, pSTAT1, and pSTAT3 expressions in circulating mononuclear cells. During the data analysis we observed that T-bet, pSTAT1, and pSTAT3 expression was not increased in circulating mononuclear cells from a relapsing-remitting (RR)MS patient with recent onset of new neurological signs due to glioblastoma multiforme. In conclusion, our patient represents an exemplary case which suggests that T-bet, pSTAT1, and pSTAT3 expression in peripheral blood mononuclear cells (PBMCs) might be useful to differentiate MS relapses from other noninflammatory diseases.

Keywords

Glioblastoma multiforme Multiple sclerosis Transcription factors Differential diagnosis 

References

  1. 1.
    Sega S, Horvat A, Popovic M (2006) Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-beta treated multiple sclerosis patients. Report of two cases. Clin Neurol Neurosurg 108:259–265. doi: 10.1016/j.clineuro.2005.11.015 PubMedCrossRefGoogle Scholar
  2. 2.
    Shuangshoti S, Hjardermaal GM, Ahmad Y et al (2003) Concurrence of multiple sclerosis and intracranial glioma. Report of a case and review of the literature. Clin Neuropathol 22:304–308PubMedGoogle Scholar
  3. 3.
    Paydarfar D, de la Monte SM (1997) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 12–1997. A 50-year-old woman with multiple sclerosis and an enlarging frontal-lobe mass. N Engl J Med 336:1163–1171. doi: 10.1056/NEJM199704173361608 PubMedCrossRefGoogle Scholar
  4. 4.
    Khan OA, Bauserman SC, Rothman MI et al (1997) Concurrence of multiple sclerosis and brain tumor: clinical considerations. Neurology 48:1330–1333PubMedGoogle Scholar
  5. 5.
    Lucchinetti CF, Gavrilova RH, Metz I et al (2008) Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131:1759–1775. doi: 10.1093/brain/awn098 PubMedCrossRefGoogle Scholar
  6. 6.
    Frisullo G, Angelucci F, Caggiula M et al (2006) pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. J Neurosci Res 84:1027–1036. doi: 10.1002/jnr.20995 PubMedCrossRefGoogle Scholar
  7. 7.
    Frisullo G, Nociti V, Iorio R et al (2007) Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. Clin Immunol 124:284–293. doi: 10.1016/j.clim.2007.05.011 PubMedCrossRefGoogle Scholar
  8. 8.
    McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127. doi: 10.1002/ana.1032 PubMedCrossRefGoogle Scholar
  9. 9.
    Weiner HLA (2008) Shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol 255(Suppl 1):3–11. doi: 10.1007/s00415-008-1002-8 PubMedCrossRefGoogle Scholar
  10. 10.
    Yang XO, Pappu BP, Nurieva R et al (2008) T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 28:29–39. doi: 10.1016/j.immuni.2007.11.016 PubMedCrossRefGoogle Scholar
  11. 11.
    Goswami S, Gupta A, Sharma SK (1998) Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG. J Neurochem 71:1837–1845PubMedCrossRefGoogle Scholar
  12. 12.
    Huettner C, Paulus W, Roggendorf W (1995) Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 146:317–322PubMedGoogle Scholar
  13. 13.
    Constam DB, Philipp J, Malipiero UV, Ten Dejke P, Schachner M, Fontana A (1992) Differential expression of transforming growth factor b-1, b-2 and b-3 by glioblastoma cells, astrocytes, and microglia. J Immunol 148:1404–1410PubMedGoogle Scholar
  14. 14.
    Zou JP, Morford LA, Chougnet C et al (1999) Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 162(8):4882–4892PubMedGoogle Scholar
  15. 15.
    Roszman TL, Brooks WH, Elliott LH (1987) Inhibition of lymphocyte responsiveness by a glial tumor cell-derived suppressive factor. J Neurosurg 67(6):874–879PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Giovanni Frisullo
    • 1
  • Agata Katia Patanella
    • 1
    • 2
  • Viviana Nociti
    • 1
    • 2
  • Alessandro Cianfoni
    • 3
  • Raffaele Iorio
    • 1
  • Assunta Bianco
    • 1
  • Alessandro Marti
    • 1
  • Pietro Attilio Tonali
    • 1
    • 2
  • Anna Paola Batocchi
    • 1
  1. 1.Department of Neuroscience, Institute of NeurologyCatholic UniversityRomeItaly
  2. 2.Fondazione Don GnocchiRomeItaly
  3. 3.Department of Radiology, Neuroradiology SectionMUSC – Medical University of South CarolinaCharlestonUSA

Personalised recommendations